In an effort to identify novel anticancer drugs, a series of novel 2,4,5-triaryl imidazole derivatives were designed against the breast cancer targets EGFR and ER. Insilco analysis of these molecules were conducted against the targets EGFR, ER for breast cancer research. The intended compounds were synthesized and characterized using MS, FTIR, and NMR. SRB assay was used to test the synthesized compounds' anticancer activity in vitro against MCF7 cell lines. Out of the 18 compounds synthesized, compounds A9 and D9 demonstrated significant antiproliferative effect with an IC50 values of 8.343μg/ml and 11.61μg/ml, respectively.